Meusinvest (Noshaq)
VC Fund
Liège, Belgium
Meusinvest (Noshaq) is a VC fund in Liège focused on Biotechnology and Health Care. Noshaq offers financial services to help businesses develop.
- Total investments:
- 82
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Meusinvest (Noshaq) invests in
Stages Meusinvest (Noshaq) invests in
Countries Meusinvest (Noshaq) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $137k–$6M
- Series A
- $3.6M–$16M
- Venture - Series Unknown
- $2M–$16M
Investment Focus
Industry
- Biotechnology 23 (28%)
- Health Care 20 (24%)
- Medical 11 (13%)
- Health Diagnostics 7 (9%)
- Medical Device 6 (7%)
Stage
- Series A 21 (26%)
- Seed 20 (24%)
- Venture - Series Unknown 11 (13%)
- Series B 8 (10%)
- Funding Round 4 (5%)
Country
- Belgium 39 (48%)
- France 14 (17%)
- Germany 2 (2%)
- United Kingdom 2 (2%)
- Luxembourg 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Balthazart
Investment Manager
|
Investment Manager | Total investments: 1 | Find email | |
Gérôme Vanherf
Program Manager
|
Program Manager | Total investments: 0 | Find email | |
Joanna Tyrekidis
CEO of Noshaq Spin-Offs; Investment Manager
|
CEO of Noshaq Spin-Offs; Investment Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amyl Therapeutics
|
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $9.6M / Series A / Sep 01, 2026 | |
|
Amyl Therapeutics
|
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $9.6M / Series A / Sep 01, 2026 | |
|
Amyl Therapeutics
|
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $9.6M / Series A / Sep 01, 2026 | |
Allegro Biotech
|
Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells). | $2.4M / Seed / Jul 03, 2025 | |
Le Fourgon
|
Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day. | $5.9M / Series A / Jan 30, 2025 | |
TrustUp
|
TrustUp is the home contractors platform, connects homeowners with verified quality home improvement. | $5.2M / Series A / Jan 01, 2025 | |
Veoware
|
Veoware provides Space satellite imagery services. | $2.8M / Venture - Series Unknown / Sep 19, 2024 | |
Brenus Pharma
|
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $25M / Series A / Sep 18, 2024 | |
Get Your Way
|
Get Your Way has redesigned connected glasses for assisted reality in the industry with a frugal innovation approach. It allows to open up to new customer segments, new applications and to be widely applicable. We have removed the barriers to the adoption of connected glasses in the industry: cost, comfort, and user interest. | $945.6K / Venture - Series Unknown / Aug 28, 2024 | |
Hedera-22
|
Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies. | $2.2M / Venture - Series Unknown / Aug 14, 2024 | |
| See all 82 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Meusinvest (Noshaq) invest in?
Meusinvest (Noshaq) invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 82 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Meusinvest (Noshaq)'s check size?
Meusinvest (Noshaq) typically joins rounds of $137k–$6M at Seed, $3.6M–$16M at Series A and $2M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Meusinvest (Noshaq) participates in.
How do I contact Meusinvest (Noshaq)?
Public channels for Meusinvest (Noshaq) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Meusinvest (Noshaq)?
The team at Meusinvest (Noshaq) includes Alain Balthazart (Investment Manager), Gérôme Vanherf (Program Manager) and Joanna Tyrekidis (CEO of Noshaq Spin-Offs; Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
